Drugs / ThisCART22
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05106946 | Oct 2021 → Oct 2023 | B-cell neoplasm | Fundamenta Therapeutics, Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04601181 | Oct 2020 → Oct 2022 | B-cell neoplasm | Fundamenta Therapeutics, Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ThisCART22 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04601181 ↗ |
| Modality | Cell therapy | “allogeneic CAR-T targeting CD22” NCT04601181 ↗ |
| Route | Other | “receive infusion of ThisCART22 cells from health donor” NCT04601181 ↗ |
| Target | CD22 | “allogeneic CAR-T targeting CD22” NCT04601181 ↗ |